134
T (2008) Assessment of a HER2 scoring sys-
tem for gastric cancer: results from a validation
study. Histopathology 52:797–805- Rüschoff J, Nagelmeier I, Baretton G, Dietel M,
Höfler H, Schildhaus HU, Büttner R, Schlake
W, Stoss O, Kreipe HH (2010) Her2 testing in
gastric cancer: what is different in comparison to
breast cancer? Pathologe 31:208–217 - Fox SB, Kumarasinghe MP, Armes JE, Bilous
M, Cummings MC, Farshid G, Fitzpatrick N,
Francis GD, McCloud PI, Raymond W, Morey
A (2012) Gastric HER2 Testing Study
(GaTHER): an evaluation of gastric/gas-
tresophageal junction cancer testing accuracy
in Australia. Am J Surg Pathol 36:577–582 - Kumarasinghe MP, de Boer WB, Khor TS, Ooi
EM, Jene N, Jayasinghe S, Fox SB (2014)
HER2 status in gastric/gastro-esophageal
junctional cancers: should determination of
gene amplification by SISH use HER2 copy
number or HER2: CEP17 ratio? Pathology
46:184–187
49. Bartley AN, Washington MK, Colasacco C,
Ventura CB, Ismaila N, Benson AB 3rd,
Carrato A, Gulley ML, Jain D, Kakar S, Mackay
HJ, Streutker C, Tang L, Troxell M, Ajani JA
(2017) HER2 testing and clinical decision
making in gastresophageal adenocarcinoma:
guideline from the College of American
Pathologists, American Society for Clinical
Pathology, and the American Society of Clinical
Oncology. J Clin Oncol 35:446–464
50. Rüschoff J, Dietel M, Baretton G, Arbogast S,
Walch A, Monges G, Chenard MP, Penault-
Llorca F, Nagelmeier I, Schlake W, Höfler H,
Kreipe HH (2010) HER2 diagnostics in gas-
tric cancer- guideline validation and develop-
ment of standardized immunohistochemical
testing. Virchows Arch 457:299–307
51. Woo CG, Ho WJ, Park YS, Park SR, Ryu MH,
Jung HY, Kang YK (2017) A potential pitfall in
evaluating HER2 immunohistochemistry for
gastric signet ring cell carcinomas. Pathology
49:38–43
Duminda Subasinghe et al.